Table 2.

Baseline Characteristics of Study Participants (N=245)

Study Characteristic	Median (IQR) or Proportion (%)
Demographic
Age (years)	Median=53.4 (45.7–59.5)
Race/Ethnicity
White	64 (26.1%)
Black/African American	92 (37.6%)
Latina	37 (15.1%)
Multiracial	29 (11.8%)
Other	23 (9.4%)
Post-menopausalc	154 (63.1%)
Substance Use
Cotinine/Nicotinee	169 (69.0%)
Cocaine/Benzoylecgoninee	129 (52.7)%
Cannabis (THC)e	125 (51%)
Levamisolee	83 (33.9%)
Methamphetaminee	71 (29.0%)
Alcohol (as determined by ethyl glucuronide)e	71 (29.0%)
Opioids other than heroine	55 (22.4%)
Cocaethylenee	42 (17.1%)
Heroin/Monoacetylmorphine-6e	5 (2.0%)
Fentanyl/Norfentanyle	6 (2.4%)
History of Chronic Health Conditions
Diabetesf	37 (15.2%)
Prior myocardial infarctionf	20 (8.2%)
Prior strokef	28 (11.5%)
HIV-positiveg	77 (31.4%)
HCV-positivef	78 (32.0%)
Pharmaceutical Drug Use
Acetaminophene	64 (26.1%)
Methadonee	53 (21.6%)
Lidocainee	38 (15.5%)
Benzodiazepinee	21 (8.6%)
Beta blockere	14 (5.7%)
Antihypertensivee	11 (4.5%)
Calcium channel blockere	10 (4.1%)
Buprenorphine/Norbuprenorphinee	1 (0.4%)
Statine	0 (0.0%)
Naloxonee	0 (0.0%)
Current Health Status
Body Mass Index (BMI)	Median=27.9 (23.2–34.0)
Systolic Blood Pressure	Median=129.0 (115.0–145.0)
Diastolic Blood Pressure	Median=85.0 (77.0–93.5)
Hypertension
No hypertension	58 (23.5%)
Elevated blood pressure (systolic ≥120 mm Hg or diastolic ≥80 mm Hg)	12 (4.9%)
Stage 1 hypertension (systolic ≥130 mm Hg or diastolic ≥80 mm Hg)	70 (28.3%)
Stage 2 hypertension (systolic ≥140 mm Hg or diastolic ≥90 mm Hg)	102 (41.3%)
Hypertensive crisis (systolic ≥180 mm Hg or diastolic ≥120 mm Hg)	5 (2.0%)
LDL cholesterol (mg/dL)	Median=93.0 (77.0–117.0)
HDL cholesterol (mg/dL)	Median=61.0 (47.0–73.0)
High-sensitivity C-Reactive Protein (hsCRP) (mg/L)	Median=3.1 (0.9–8.9)
High-sensitivity Troponin I (ng/L)	Median=2.0 (1.0–3.0)

^c>1 year since last menstrual period

^ePositive toxicology results

^fSelf-reported

^gELISA test results